Zevra Therapeutics to acquire Acer Therapeutics
Zevra Therapeutics, Inc., a rare disease company melding science, data and patient need to create transformational therapies for diseases with limited or no treatment options, and Acer Therapeutics Inc., a pharmaceutical company focused on development and commercialization of therapies for rare and life-threatening diseases, announced the companies have entered into a definitive agreement pursuant to which Zevra would acquire Acer in a merger transaction having a total potential value for Acer stockholders of up to $91 million
The merger is expected to expand Zevra's rare disease portfolio, as well as increase and diversify its revenues with the addition of a U.S. commercial asset, Olpruva, indicated for the treatment of UCDs (urea cycle disorders).
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.
